These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26824884)

  • 21. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group.
    Bruera E; Sloan P; Mount B; Scott J; Suarez-Almazor M
    J Clin Oncol; 1996 May; 14(5):1713-7. PubMed ID: 8622092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.
    Wallace M; Moulin DE; Rauck RL; Khanna S; Tudor IC; Skowronski R; Thipphawong J
    J Opioid Manag; 2009; 5(2):97-105. PubMed ID: 19507806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
    Rauck R; Rapoport R; Thipphawong J
    Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of analgesia in human chronic pain. Randomized double-blind crossover study of once daily repro-dose morphine versus MST continus.
    Peat S; Sweet P; Miah Y; Barklamb M; Larsen U
    Eur J Clin Pharmacol; 1999 Oct; 55(8):577-81. PubMed ID: 10541775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
    Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose conversion between tapentadol immediate and extended release for low back pain.
    Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
    Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.
    Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
    Int J Clin Pract; 2007 Oct; 61(10):1671-6. PubMed ID: 17877652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Oral osmotic hydromorphone (OROS) in patients with chronic severe pain due to osteoarthritis under daily routine conditions].
    Müller-Schwefe GH; Blimke B; Hesselbarth S; Giesecke T
    MMW Fortschr Med; 2014 Apr; 156 Suppl 1():23-9. PubMed ID: 24930329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study.
    Song EK; Shim H; Han HS; Sun D; Lee SI; Kang MH; Lee K; Cho D; Cho IS; Park SY; Kim S; Yim CY
    Pain Res Manag; 2015; 20(6):293-9. PubMed ID: 26474382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief).
    Inoue S; Saito Y; Tsuneto S; Aruga E; Ide A; Kakurai Y
    J Pain Res; 2017; 10():1953-1962. PubMed ID: 28860850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized study to compare the efficacy and safety of extended-release and immediate-release tramadol HCl/acetaminophen in patients with acute pain following total knee replacement.
    Park YB; Ha CW; Cho SD; Lee MC; Lee JH; Seo SS; Kang SB; Kyung HS; Choi CH; Chang N; Rhim HY; Bin SI
    Curr Med Res Opin; 2015 Jan; 31(1):75-84. PubMed ID: 25299350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
    Bartoli A; Michna E; He E; Wen W
    Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.
    Beaulieu AD; Peloso P; Bensen W; Clark AJ; Watson CP; Gardner-Nix J; Thomson G; Piraino PS; Eisenhoffer J; Harsanyi Z; Darke AC
    Clin Ther; 2007 Jan; 29(1):49-60. PubMed ID: 17379046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: pooled analysis of 13 studies.
    Hale ME; Wallace MS; Taylor DR; Kutch M; Nalamachu S
    J Opioid Manag; 2012; 8(5):299-314. PubMed ID: 23247907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.